Posts for Ticker ‘MEDX’

Top Day Trader Alerts (JASO, GRMN, YRCW, JAZZ, MEDX, BMY, PETD, TOL, XHB, BRCM)

These are this morning’s top day trader alerts and most active in price and volume.  We have more detailed analysis and data on price and volume with links through to each at VSInvestor.com:

JA Solar Holding Co. (NASDAQ: JASO) is down close to 10% after poor results.

Garmin Ltd. (NASDAQ: GRMN) is down over 5% on a key analyst downgrade.

YRC Worldwide, Inc. (NASDAQ: YRCW) was down over 7% on an analyst downgrade.

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) was up almost 20% on an unexpected profit.

Medarex Inc. (NASDAQ: MEDX) is seeing very unusual merger arb volume after the Hart-Scott-Rodino merger review period for the Bristol-Myers Squibb (NYSE: BMY) buyout has expired.

Petroleum Development Corporation (NASDAQ: PETD) is down 5% and will be an exponential volume mover on the secondary offering.

Toll Brothers (NYSE: TOL) has some sales gains data that is strong enough to lift the SPDR S&P Homebuilders (NYSE: XHB).

This was not seen until a post-close review, but Broadcom Corp. (NASDAQ:BRCM) was seeing some very unusual PUT OPTIONS TRADING yesterday.

JON C. OGG
AUGUST 12, 2009

Posted on: August 12, 2009 – 9:26 am in Pre-Market Activity, Trading Alert, , , , , , , , , ,

Media Digest 7/24/2009 Reuters, WSJ, NYTimes, FT. Bloomberg

newspaperReuters: Microsoft’s (MSFT) results and forecast were weak.

Reuters:   CIT (CIT) may sell its aviation finance business.

Reuters:   Fatigue at the Fed is leading to questions about its expanded role.

Reuters:   Twitter will pitch add-on tools to businesses.

Reuters:   Vodafone (VOD) stuck to its full-year forecast.

Reuters:   Amex (AXP) and Capital One (COP) had large cars losses. Read More »

Posted on: July 24, 2009 – 2:54 am in Press Digest, , , , , , , , , , , , , ,

Bristol-Myers Gets Key Assets With A Medarex Deal (BMY, MEDX, ABT, JNJ, AMGN, WYE)

biotech

Bristol Myers Inc. (NYSE: BMY) plans to spend $2.4 billion to buy partner Medarex Inc. (Nasdaq: MEDX). It will get a great deal beyond the cancer monoclonal antibody that developed together.

The Medarex pipeline has substantial value.

The monoclonal antibody ipilimumab is by far the main reason that Bristol pulled the trigger. It is currently in Phase III trials for both metastatic melanoma and hormone-refractory prostate cancer. Read More »

Posted on: July 23, 2009 – 9:12 am in Drug companies, Editor's Picks, Mergers and Buy Outs, Pharmaceuticals, , , , ,

Top Day Trader Alerts (MEDX, ISRG, OREX, CELG, EBAY, SNDK, PSUN, QCOM)

The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis at VSInvestor.com:

Medarex Inc. (Nasdaq: MEDX) shares are up about 90 percent after Bristol-Myers Squibb Co. (NYSE: BMY) said it plans to buy the company for $2.4 billion, or $16 a share.

Pacific Sunwear of California Inc. (Nasdaq: PSUN) shares are getting hit on a second-quarter warning.

Orexigen Therapeutics Inc. (Nasdaq: OREX) shares are falling, and are among the most actively traded Nasdaq stocks after the company proposed a 9 million-share offering.

Celgene Corp. (Nasdaq: CELG) shares are up more than 10 percent on stronger-than-expected revenue and net procedure sales growth.

Intuitive Surgical Inc. (Nasdaq: ISRG) shares are up strongly on better-than-expected earnings and strong procedure growth guidance.

eBay Inc. (Nasdaq: EBAY) shares are up after beating quarterly expectations and guiding third-quarter revenue slightly higher.

SanDisk Corp. (Nasdaq: SNDK) shares are down after it beat Q2 expectations, but gave cautious guidance.

Qualcomm Inc. (Nasdaq: QCOM) shares are falling after it beat expectations, but only guided in-line, amid analyst concerns about average selling prices.

– The 24/7 Wall St. Team

Posted on: July 23, 2009 – 7:47 am in Pre-Market Activity, Trading Alert, , , , , , , ,

Media Digest 7/23/2009 Reuters, WSJ, NYTimes, FT, Bloomberg

newspaperReuters:   Obama says healthcare reform is essential to the recovery.

Reuters:   CIT (CIT) bond advisers will push for Chapter 11.

Reuters:   Democrats will fight with banks on consumer agency.

Reuters:   Amazon (AMZN) bought Zappos for $829 million.

Reuters:   Porsche approved Qatar talks and fired its CEO.

Reuters:   Bristol-Myers (BMY) bought Medarx (MEDX) for $2.4 billon. Read More »

Posted on: July 23, 2009 – 2:57 am in Press Digest, , , , , , , , , , , , , , , ,

Top Analyst Downgrades (ARQL, ASML, CSCO, MEDX, MSFT)

These are the top analyst downgrades and cautious research calls we have seen from Wall Street this Thursday morning:

ArQule (ARQL) Cut to Sell at UBS.
ASML (ASML) Cut to Neutral at Piper Jaffray.
Cisco Systems (CSCO) Started as Hold at Argus.
Medarex (MEDX) Cut to Neutral at UBS.
Microsoft (MSFT) Cut to Sell at Argus.

JON C. OGG

Posted on: July 16, 2009 – 7:15 am in Analyst Calls, , , , ,

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies:  Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted on: May 27, 2009 – 1:34 pm in Biotech, Drug companies, FDA, Medical, Pharmaceuticals, , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Previewing 2009 ASCO Abstracts (ABII, ALTH, ARQL, CLDX, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, OGXI, OSIP, PPHM, PFE, SNTA, ZIOP)

We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009.  At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE:  LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).

You can see that full pre-report here at BiohealthInvestor.com.  As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.

Posted on: May 14, 2009 – 4:56 pm in Biotech, Drug companies, Medical, Pharmaceuticals, , , , , , , , , , , , , , , , , , ,

Medarex Positive Data in Rheumatoid Arthritis Trial (MEDX)

Medarex, Inc. (NASDAQ: MEDX) announced that its wholly owned MDX-1100 met its primary endpoints for patients receiving methotrexate in a Phase II ‘proof of concept’ trial in patients with active rheumatoid arthritis.  The trial indicated that three-times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks when compared to placebo.   So far we have shares indicated 3% higher on the news.

Read the full story at BioHealthInvestor.com.

Posted on: May 14, 2009 – 7:05 am in Biotech, Drug companies,

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks.  The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month.  The following companies which are presenting data:

  • Allos Therapeutics, Inc. (NASDAQ: ALTH)
  • Amgen (NASDAQ: AMGN)
  • ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
  • Array BioPharma, Inc. (NASDAQ: ARRY)
  • AstraZeneca’s (NYSE: AZN) Medimmune unit
  • Biogen Idec Inc. (NASDAQ: BIIB)
  • Celgene Corporation (NASDAQ: CELG)
  • Curis, Inc. (NASDAQ: CRIS)
  • Immunomedics, Inc. (Nasdaq: IMMU)
  • ImmunoGen, Inc. (Nasdaq: IMGN)
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
  • Medarex, Inc. (Nasdaq: MEDX)
  • Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Pfizer (NYSE: PFE)
  • Pharmacyclics, Inc. (NASDAQ: PCYC)
  • SuperGen Inc. (NASDAQ:SUPG)
  • Telik, Inc. (Nasdaq: TELK)
  • Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)

You can see a full summary of the data being presented at BioHealthInvestor.com site.  There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.

JON C. OGG

Posted on: April 17, 2009 – 2:05 pm in Biotech, Calendar, Drug companies, , , , , , , , , , , , , , , , , , ,

Top 10 Early Analyst Upgrades & Downgrades (FUL, OZM, REP, TOL, DOV, EMR, GA, GSK, MEDX, RDS-A)

Money_stack_picThese are ten of the top pre-market early bird upgrades and downgrades we are seeing from analysts this Friday morning:

  • H.B. Fuller (NYSE: FUL) Raised to Overweight at JPMorgan.
  • Och-Ziff Capital (NYSE: OZM) Started as Buy at Jefferies.
  • Repsol YPF (NYSE: REP) Raised to Buy from Hold at ING; Raised to Hold from Sell at Soc-Gen.
  • Toll Brothers (NYSE: TOL) Started as Outperform at KBW.
  • Dover (NYSE: DOV) Cut to Underweight at JPMorgan.
  • Emerson Electric (NYSE: EMR) Cut to Underweight at JPMorgan.
  • Giant Interactive (NYSE: GA) Cut to Perform at Oppenheimer.
  • GlaxoSmithkline (NYSE: GSK) Cut to Neutral from Buy at UBS.
  • Medarex (NASDAQ: MEDX) Started as Sell at Merriman Curhan Ford.
  • Royal Dutch Shell (NYSE: RDS-A) Cut to Hold from Buy at ING.

Jon C. Ogg
November 14, 2008

Posted on: November 14, 2008 – 7:26 am in Analyst Calls, , , , , , , , , ,

Medarex & Bristol-Myers Show Positive Metastatic Melanoma Data (BMY, MEDX)

There is some very hopeful data out there this morning on cancer survival.  Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma in Stage III or IV levels who had previously been treated showing that approximately half of patients who received ipilimumab remained alive beyond one year.

Read More »

Posted on: September 15, 2008 – 9:26 am in Biotech, Drug companies, ,

Top Pre-Market Analyst Downgrades (AUDC, BDX, FUL, LEH, MEDX, NVDA, PDLI)

These are some of the early bird analyst downgrades and negative calls we are seeing this Thursday morning with more than two hours to the open:

  • AudioCodes (AUDC) cut to neutral at Merrill Lynch.
  • Becton Dickinson (BDX) cut to neutral at Credit Suisse.
  • H.B. Fuller (FUL) cut to neutral at JPMorgan.
  • Lehman Brothers (LEH) cut to neutral at Goldman Sachs; cut to Hold at Citigroup.
  • Medarex (MEDX) cut to neutral at JPMorgan.
  • NVIDIA (NVDA) cut to equal weight at Lehman.
  • PDL BioPharma (PDLI) cut to underweight at JPMorgan.

Jon C. Ogg
September 11, 2008

Posted on: September 11, 2008 – 6:19 am in Analyst Calls, , , , , , ,

Biotech Business Daily (CHTP, CRXL, LLY, IOMI, MEDX, TRCA)

Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) falling today after first quarter earnings showed wider losses than first quarter 2007. Net loss was $8.7 million compared to a loss of $3.8 million in 2007. The wider loss was driven primarily through increased research and development expenses. Shares are down $0.44, or 8%, at $4.69. The 52-week range is $4.45 to $8.41.

Crucell NV (NASDAQ: CRXL) up today after cutting its net loss in half, posting $13.2 million in losses. The company has $120 million in new contracts for pediatric vaccine Quinvaxem to look forward to in the next two years. Revenues are on track to meet guidance. Also, the company announced this morning that Phase II testing of rabies monoclonal antibody combination product will begin in the Philipines. The product has already commenced testing in the U.S. Shares are up over 8% at $19.43 in mid-day trading. The 52-week range is $12.76 to $24.81.

Eli Lilly & Co. (NYSE: LLY) announced a partnership with TopCoder today, allowing Eli Lilly to outsource complex drug discovery through complex technology processes to the software developer. Shares are down less than 1% at $47.82. The 52-week range is $46.60 to $60.00.

Iomai Corporation (NASDAQ: IOMI) is soaring to new highs today after receiving a $189 million offer yesterday from vaccine maker Intercell AG which trades on the Vienna exchange. The offer of $6.60 per share is a 126% premium to the closing share price Monday of $2.92. As a result of the acquisition, Intercell will have full rights to Iomai’s diarrhea vaccine set to enter Phase III trials in early 2009. Shares are up a whopping 116% at $6.33 in mid-day trading on extremely high relative trading volume. The 52-week range for the biotech company is $0.70 to $4.70.

Medarex Inc. (NASDAQ: MEDX) received a boost after the company was upgraded by Needham & Co. to "Buy" from "Hold." Shares are up $0.56, or almost 8%, at $7.59. The 52-week range is $6.88 to $ 18.23.

Tercica Inc. (NASDAQ: TRCA) dropping over 15% today after posting wider net losses yesterday. The endocrine health biotech company generated a net loss of $17.5 million for the quarter, compared to a net loss of $12.4 million in the first quarter of 2007. Shares down $0.77 at $4.22 in early morning trading. The 52-week range is $4.27 to $8.11.

Rachel Lopez
May 12, 2008

Posted on: May 13, 2008 – 12:10 pm in Biotech, , , , , ,

Medarex Says Forget Pfizer, Its Own Melanoma Study Continues (MEDX, PFE, BMY)

Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma.  The company says that there are key differences between Pfizer’s discontinuing its Phase 3 clinical trial of front-line treatment of tremelimumab compared to chemotherapy in patients with advanced melanoma.

Pfizer’s tremelimumab and Medarex’s ipilimumab do have a similar mechanism and have been considered by some as similar molecules, and it is natural to attempt to draw parallels between the two molecules.

But Medarex wants to clarify some issues.  The two antibodies are different molecules, and results from one antibody program may not be indicative of the same results from another program.  While it previously reported that results from the Phase 2 study did not meet the primary endpoint, the three studies in its Phase 2 program were suggestive of ipilimumab’s potential for clinical anti-tumor activity and are under discussion with regulatory agencies.  Medarex’s ongoing ipilimumab Phase 3 program for front-line treatment of advanced melanoma is different in design from the Pfizer trial, and it is too early to draw any clinical conclusions from the Pfizer announcement and a recent review of its ongoing Phase 3 trial by the Data Monitoring Committee indicated that the Medarex trial should continue.

Lastly, Medarex noted that Bristol-Myers Squibb Company (NYSE: BMY) is its partner for ipilimumab and its studies are continuing to move forward; and prior guidance is unchanged and regulatory discussions are pending.

Medarex shares were up about 2% shortly after it issued this clarification statement.  Unfortunately shares are back to down marginally by 0.25% at $7.61 right before the open.  As we have noted, this is the largest potential candidate it has right now.  But this company also has many partnerships and an extensive pipeline of potential drug candidates, and it continues to win milestones on other studies and candidates.

Jon C. Ogg
April 3, 2008

Posted on: April 3, 2008 – 8:27 am in Biotech, Drug companies, , ,

The 52-Week Low Club (SGP)(PAY)(DEEP)

Superior Offshore (DEEP) Company warns of liquidity problems. Down to $1.20 from 52-week high of $19.58.

Medarex (MEDX) Pfizer ends joint drug trial. Sells off to $7.44 from 52-week high of $18.23.

Crocs (CROX) Downgrade by JP Morgan. Falls to $15.53 from 52-week high of $75.21.

Riverbed Technology (RVBD) No big, bad news. Stock down to $13.62 from 52-week high of $52.81.

Verifone (PAY) CFO is out after restatement. Shares drop to $12.65 from 52-week high of $50.

Schering-Plough (SGP) Fitch downgrades after negative comment on key drug product. Falls to $13.91 from 52-week high of $33.81.

Douglas A. McIntyre

Posted on: April 2, 2008 – 2:45 pm in HI/LOW, , , , , ,

Medarex Tanks On Pfizer Study Halt (PFE, MEDX)

Medarex Inc. (NASDAQ: MEDX) Saw shares plummet in pre-market trading.  Pfizer Inc. (NYSE: PFE) has ended a Phase III clinical trial of tremelimumab in patients with advanced melanoma after a review of interim data showed that the drug was not better than standard chemotherapy.  Unfortunately, Medarex was the beneficiary of CP-675,206 (tremelimumab), and it would have received a large stream of royalties had this worked.

While this is obviously bad news, this probably should have been expected after its prior disclosures.  The company had previously disclosed that results and hopes seen in early trials had not come to fruition in larger and broader study groups.  It’s too bad, too.  Metastatic melanoma (skin cancer that spread to other parts of your body) is currently a death sentence. 

Shares are down 16% in pre-market activity this morning to $7.80.  Its 52-week trading range is $7.70 to $18.23.

Obviously there are concerns over any biotech when a molecule fails to generate results.  But we would note that Medarex has a significant candidate pipeline and has many active partnerships with other major drug and biopharma players.

Jon C. Ogg
April 2, 2008

Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: April 2, 2008 – 8:15 am in Biotech, Drug companies, ,

Melanoma Patients Have Another Hope With New Orphan Drug Designation (ADH, MEDX)

Adherex Technologies Inc. (AMEX: ADH) has announced that it has received an orphan drug designation for its ADH-1 from the FDA for the use of ADH-1 in conjunction with melphalan for the treatment of Stage IIB/C, III, and IV malignant melanoma.

Adherex is currently conducting a Phase IIb expansion trial in melanoma using systemic ADH-1 in combination with regional melphalan; and Adherex is also evaluating the synergy of systemic ADH-1 in combination with regionally-infused melphalan for the treatment of melanoma in a Phase I/IIb trial. Another Phase I trial is also nearing completion at US Oncology where systemic ADH-1 is being evaluated in combination with three different chemotherapies.

The FDA orphan drug designation could be substantial for this company.  It "could" provide incentives such as funding for clinical studies, study assistance, a waiver of FDA user fees, potential tax credits, and up to seven years of market exclusivity upon marketing approval.

If you will recall the blow-up at Medarex (NASDAQ: MEDX) and the massive options speculation that was trading around the stock before the FDA review, the mere potentiality of this is huge.  This is a very different company and the treatment here is a different treatment as this is malignant.  But traders will likely tie the two at least in relation to each other.  Melanoma is a very under-treated disease in the US and throughout the world with a mega-blockbuster drug potential.  Metastatic melanoma is currently nothing short of a death sentence.

Jon C. Ogg
February 22, 2008

Posted on: February 22, 2008 – 8:52 am in Biotech, FDA, , , ,

Top 10 Pre-Market Analyst Calls (ADBL, GOOG, LOW, MXIM, MEDX, MS, MOT, OI, TIVO, DIS)

Below are ten of the top analysts calls that247WallSt.com is looking at this morning:

  • Audible (NASDAQ: ADBL) downgraded to Hold from Buy at Citigroup.
  • Google (NASDAQ: GOOG) downgraded to Hold from Buy at Jefferies.
  • Lowe’s (NYSE: LOW) downgraded to Hold from Buy at Citigroup.
  • Maxim Integrated (NASDAQ: MXIM) downgraded to Hold from Buy at Jefferies.
  • Medarex (NASDAQ: MEDX) raised to Neutral from Sell at Banc of America.
  • Morgan Stanley (NYSE: MS) downgraded to Neutral from Buy at Goldman Sachs.
  • Motorola (NYSE: MOT) raised to Buy at Citigroup.
  • Owens-Illinois (NYSEO: OI) raised to Buy from Hold at Deutsche Bank.
  • TiVo (NASDAQ: TIVO) downgraded to Underperform from Market Perform at FBR.
  • Walt Disney (NYSE: DIS) raised to Outperform from Market Perform at Oppenheimer.

Jon C. Ogg
February 1, 2008

Posted on: February 1, 2008 – 7:43 am in Analyst Calls, , , , , , , , , ,

Top 10 Pre-Market Analyst Calls (ADCT, ARRS, EL, FLML, GERN, HD, LOW, MCD, MEDX, NOVL, NMX, DIS)

These are not the only pre-market analyst calls that are moving stocks, but these are the calls that 247WallSt.com is focusing on:

  • ADC Telecom (NASDAQ: ADCT) and Arris (NASDAQ: ARRS) raised to Buy at UBS.
  • Estee Lauder (NYSE: EL) raised to Buy at UBS.
  • Flamel (NASDAQ: FLML) raised to But at Merriman Curhan Ford.
  • Geron (NASDAQ: GERN) raised to Buy at UBS.
  • Home Depot (NYSE: HD) and Lowe’s (NYSE: LOW) started as Market Perform at Morgan Keegan.
  • McDonald’s (NYSE: MCD) downgraded to Peer Perform at Bear Stearns.
  • Medarex (NASDAQ: MEDX) started as Buy at UBS.
  • Novell (NASDAQ: NOVL) raised to Buy at Jefferies.
  • NYMEX (NYSE: NMX) downgraded to Hold at Citigroup.
  • Walt Disney (NYSE: DIS) downgraded to Sell at Citigroup.

Jon C. Ogg
January 29, 2008

Posted on: January 29, 2008 – 7:54 am in Analyst Calls, , , , , , , , , , , ,